The use of opioids in late-stage COPD—Where are we now?

Thomas J. Altree, David C. Currow

Research output: Contribution to journalComment/debate

1 Citation (Scopus)
124 Downloads (Pure)

Abstract

Key points

The use of regular, low-dose morphine to reduce symptomatic chronic breathlessness was identified in a systematic review and meta-analysis.

Since that meta-analysis, three adequately powered studies have not confirmed its findings in people with moderate to severe chronic breathlessness.

Two of those subsequent studies identified that people with COPD and severe breathlessness (housebound or breathless when dressing or undressing) may derive symptomatic benefits safely.

A short trial (1 week) of regular, low-dose, sustained-release morphine (10 mg/24 h) can be considered in such patients.
Original languageEnglish
Pages (from-to)1017-1019
Number of pages3
JournalRespirology
Volume29
Issue number12
Early online date7 Oct 2024
DOIs
Publication statusPublished - Dec 2024

Keywords

  • chronic obstructive pulmonary disease
  • COPD
  • meta-analysis

Fingerprint

Dive into the research topics of 'The use of opioids in late-stage COPD—Where are we now?'. Together they form a unique fingerprint.

Cite this